308 related articles for article (PubMed ID: 29733876)
21. Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery.
Li N; Zhao Q; Shu C; Ma X; Li R; Shen H; Zhong W
Int J Pharm; 2015 Jan; 478(2):644-54. PubMed ID: 25510600
[TBL] [Abstract][Full Text] [Related]
22. Design and Fabrication of Magnetically Responsive Nanocarriers for Drug Delivery.
Kralj S; Potrc T; Kocbek P; Marchesan S; Makovec D
Curr Med Chem; 2017; 24(5):454-469. PubMed ID: 27528059
[TBL] [Abstract][Full Text] [Related]
23. Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery.
Dhas NL; Kudarha RR; Acharya NS; Acharya SR
Crit Rev Ther Drug Carrier Syst; 2018; 35(1):1-64. PubMed ID: 29611470
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
Elbialy NS; Fathy MM; Khalil WM
Int J Pharm; 2015 Jul; 490(1-2):190-9. PubMed ID: 25997662
[TBL] [Abstract][Full Text] [Related]
25. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.
Krishnaiah YS; Khan MA
Pharm Dev Technol; 2012; 17(5):521-40. PubMed ID: 22681390
[TBL] [Abstract][Full Text] [Related]
26. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
27. Preparation and characterization of superparamagnetic iron oxide nanoparticles for magnetically guided drug delivery.
Kumar P; Agnihotri S; Roy I
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):43-46. PubMed ID: 30880956
[TBL] [Abstract][Full Text] [Related]
28. Magnetic single-walled carbon nanotubes as efficient drug delivery nanocarriers in breast cancer murine model: noninvasive monitoring using diffusion-weighted magnetic resonance imaging as sensitive imaging biomarker.
Al Faraj A; Shaik AP; Shaik AS
Int J Nanomedicine; 2015; 10():157-68. PubMed ID: 25565811
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells.
Pereira I; Sousa F; Kennedy P; Sarmento B
Int J Pharm; 2018 Oct; 549(1-2):397-403. PubMed ID: 30110619
[TBL] [Abstract][Full Text] [Related]
30. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
31. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy.
Liu X; Liu C; Zheng Z; Chen S; Pang X; Xiang X; Tang J; Ren E; Chen Y; You M; Wang X; Chen X; Luo W; Liu G; Xia N
Adv Mater; 2019 Apr; 31(17):e1808294. PubMed ID: 30848011
[TBL] [Abstract][Full Text] [Related]
32. A magnetically guided anti-cancer drug delivery system using porous FePt capsules.
Fuchigami T; Kawamura R; Kitamoto Y; Nakagawa M; Namiki Y
Biomaterials; 2012 Feb; 33(5):1682-7. PubMed ID: 22123601
[TBL] [Abstract][Full Text] [Related]
33. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
[TBL] [Abstract][Full Text] [Related]
34. Intrathecal magnetic drug targeting using gold-coated magnetite nanoparticles in a human spine model.
Lueshen E; Venugopal I; Kanikunnel J; Soni T; Alaraj A; Linninger A
Nanomedicine (Lond); 2014; 9(8):1155-69. PubMed ID: 23862614
[TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer management: strategies in drug delivery.
Singh P; Waghambare P; Khan TA; Omri A
Expert Opin Drug Deliv; 2022 Jun; 19(6):653-670. PubMed ID: 35656670
[TBL] [Abstract][Full Text] [Related]
36. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
37. Magnetic targeting for site-specific drug delivery: applications and clinical potential.
Polyak B; Friedman G
Expert Opin Drug Deliv; 2009 Jan; 6(1):53-70. PubMed ID: 19236208
[TBL] [Abstract][Full Text] [Related]
38. Novel epigenetic target therapy for prostate cancer: a preclinical study.
Naldi I; Taranta M; Gherardini L; Pelosi G; Viglione F; Grimaldi S; Pani L; Cinti C
PLoS One; 2014; 9(5):e98101. PubMed ID: 24851905
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
40. Albumin-based micro-composite drug carriers with dual chemo-agents for targeted breast cancer treatment.
Abedin F; Anwar MR; Asmatulu R; Yang SY
J Biomater Appl; 2015 Jul; 30(1):38-49. PubMed ID: 25638169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
